Amneal Pharmaceuticals, Inc. (AMRX) Wins EU Approval for Adcomfo Biosimilar
Amneal Pharmaceuticals (AMRX) received EU approval for Adcomfo, a biosimilar to XOLAIR. The drug met primary efficacy and safety endpoints in a 600-patient study. Amneal acquired the biosimilar program from Kashiv in 2026. ADVANZ PHARMA holds European commercialization rights. FDA decision on U.S. application is pending.
How this was made

The 30-second read
Why it matters
Regulatory approval reduces a key execution risk for the Adcomfo biosimilar and can improve the probability-weighted value of the program, but the article does not provide US FDA timing or financial impact.
Market read
A concrete EU regulatory milestone for AMRX’s biosimilar program, with confirmatory-study results, is a tradable de-risking event.
What to watch
The article does not quantify expected EU uptake, pricing, or launch date; commercialization rights are held by ADVANZ PHARMA, which can dilute how much AMRX captures near-term economics.
Background
The EC authorization follows an EMA committee opinion in September and UK authorization in March, and the program is described as acquired with Kashiv in August 2026.
Ticker impact
Amneal (AMRX) received European Commission marketing authorization for its Adcomfo (omalizumab) biosimilar, with a 600-patient confirmatory study meeting efficacy and safety endpoints.
Likely upward bias as the market prices in reduced regulatory risk and improved commercialization prospects for the biosimilar program.
The article is a direct regulatory milestone (EC marketing authorization) with specific confirmatory-study details, but it does not provide financial guidance, launch timing, or sales traction.
Market effects
Supports broader biosimilar sentiment in Europe by signaling continued regulatory acceptance of monoclonal antibody biosimilars.
Positive for EU biosimilar commercialization outlook, potentially affecting competitive dynamics versus originators and other biosimilar entrants.
May modestly influence global expectations for Amneal’s pipeline progress, but the article notes the larger catalyst would be FDA action in the US.
Counterpoint
EU approval may already be partially anticipated by the market given prior EMA committee opinion and UK authorization, limiting incremental upside until launch and sales data arrive.
Key entities
- companyAmneal Pharmaceuticals, Inc.
Subject of the article, granted EU marketing authorization for Adcomfo (omalizumab) biosimilar.
- regulatorEuropean Commission
Granted marketing authorization for Adcomfo in the EU.
- commercial partnerADVANZ PHARMA
Holds European commercialization rights per the article.
- reference productXOLAIR
Originator product to which Adcomfo is compared for biosimilarity.
